Genmab A/S Sponsored ADR (NASDAQ: GMAB) Financial Performance and Investor Sentiment

Earnings per share of $0.35 fell short of the estimated $0.46, while revenue slightly surpassed expectations at approximately $1.06 billion.A 15.1% decline in short interest suggests a positive shift in investor sentiment towards GMAB.Institutional investors like Alliancebernstein L.P. have increased their stakes, indicating confidence in the company's potential despite its earnings miss.Genmab A/S Sponsored ADR (NASDAQ:GMAB) is a biotechnology company focused on developing antibody therapeutics for cancer ...